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Abstract
Recombinase mediated cassette exchange (RMCE) is a two-step process leading to genetic modification in a specific
genomic target sequence. The process involves insertion of a docking genetic cassette in the genome followed by DNA
transfer of a second cassette flanked by compatible recombination signals and expression of the recombinase. Major
technical drawbacks are cell viability upon transfection, toxicity of the enzyme, and the ability to target efficiently cell types
of different origins. To overcome such drawbacks, we developed an RMCE assay that uses an integrase-deficient lentivirus
(IDLV) vector in the second step combined with promoterless trapping of double selectable markers. Additionally,
recombinase expression is self-limiting as a result of the exchangeable reaction, thus avoiding toxicity. Our approach
provides proof-of-principle of a simple and novel strategy with expected wide applicability modelled on a human cell line
with randomly integrated copies of a genetic landing pad. This strategy does not present foreseeable limitations for
application to other cell systems modified by homologous recombination. Safety, efficiency, and simplicity are the major
advantages of our system, which can be applied in low-to-medium throughput strategies for screening of cDNAs, non-
coding RNAs during functional genomic studies, and drug screening.
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Introduction
Genetic modification of cells in human and experimental models is
essential when deciphering gene-encoded information during
developmental, physiological, and pathological states. A complete
understanding ofthe mechanismsgoverning gene function isessential
in areas such as development of regenerative and reparative
medicine, gene therapy, genetic models of disease and reliable
systems in drug discovery. One of the uses of homologous
recombination (HR) is to generate stable ‘‘knock-in’’ cell lines
(embryonic, iPSCs, or primary) with selectable markers expressing
specific cDNAs or RNAi that make it possible to purify specific cell-
derived cell types from a mixed population and to decipher their roles
in cellstemness, differentiation, and fate, as well as in homeostasis and
disease [1]. However, efficient and safe genetic targeting at stable and
harmless loci remains elusive and is a limitation for low-to-medium
throughput strategies. Genetic modification based on homologous
recombination (HR), heterologous site-specific recombinase (SSR),
and recombinase-mediated cassette exchange (RMCE) has been
widely used in chromosomal targeting, although currently available
technology is laborious [2,3,4,5]. Zinc-finger nuclease–based and
meganuclease-based [6,7,8] technologies have recently been designed
for site-specific editing and are proving to be exceptionally promising
tools, although they are time-consuming and expensive. In addition,
these approaches are either inefficient or restricted in their
applicability, thus preventing them from being used in large-scale
functional genetic screening studies.
At present, the most efficient strategies for gene targeting
combine tagged cellular systems containing recombination target
sites (RTs) from phages (cre, phiC31)[9] or yeasts (flp)[10] with
selected harmless genetic loci that are prone to recombination, for
example, ROSA26 [11], hprt [12,13], AAVS1 [6]. The generation of
suchtaggedcellsbyHRisarelativelyslowprocessthatoccursatlow
frequency and requires selection and analysis of resistant clones.
Tagged cells can be converted to express any sequence by gene
replacement using genetic cassettes flanked by compatible RTs
together with delivery of suitable recombinase. Gene targeting has
been achieved in several loci of hES cells [11,12] and site-specific
recombinants can be enriched by RMCE at specific loci, with no
apparent loss of the in vitro properties of hESCs [13].
No definite systems have been described to date for efficient
cassette replacement by RMCE. Available approaches, such as
application of cationic compounds, electroporation, and adenovi-
ruses [14,15,16] , compromise the viability of cells and are
complicated by restrictions that affect several cell types. In
addition, overexpression of cre can be toxic for certain cells and
tissues [17]. Consequently, novel approaches are necessary to
improve RMCE frequencies and the limited expression of the
recombinase. Vectors to ease cloning, manipulation, and high
transduction efficiency in wide cell-types represent a challenge in
hESC research [14]. Combined with tagged cells designed to
promote efficient recombination and simple markers for the rescue
of legitimate targeted clones, these vectors could make it possible
to develop versatile cellular systems for gene studies.
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requirements by combining the advantages of RMCE [2] with the
powerful technology derived from integrase-deficient lentiviral
vectors (IDLV). The strategy takes advantage of the easy manage-
ment of lentivirus-derived vectors, the simple handling and cloning
steps required for vector production, and the highly efficient
transduction of almost every cell type assayed [18]. Envelope
pseudotyping [19] and transductional targeting combining promoters
and biosensors [20] have made it possible to transduce cells of several
origins, tissue type, or developmental status using lentiviral vectors
[21]. Lentiviral integration–dependent genotoxicity is no longer a
major drawback, thanks to the generation of episomal viral circular
forms by point-mutated integrase during IDLV replication [22].
These characteristics underlie the versatility of lentiviruses, irrespec-
tive of the target cell type (eg, primary or established cell lines, human
or mouse embryonic stem cells).
Our strategy, which we call KAS-TRINA (see below), uses very
high-frequency promoter trapping to detect and rescue cells
undergoing legitimate gene replacement by recombination at a
pre-targeted locus. We adopt a proof-of-principle approach using
a novel strategy modeled on a human cell line, but which could be
extended to other cell systems.
Materials and Methods
Cell culture
The human embryonic kidney cell lines HEK293A (ATCC
#CRL-1573) and HEK293T (HEK 293FT, Invitrogen, Prat del
Llobregat, Barcelona, Spain) were cultured under standard
conditions in DMEM (Lonza, Lonza Ibe ´rica SA, Barcelona,
Spain) supplemented with 1% Glutamax (Invitrogen), 10 mg/ml
antibiotics (penicillin streptomycin) and 10% foetal bovine serum
(Gibco, Invitrogen).
After the selection of cells with hygromycin B solution (Sigma
Aldrich) at 50 mg/mL, resistant colonies were stained with cristal-
violet on methanol fixed plates, washed and air dried.
Plasmid construction
To construct the hROSA26-targeting vector, we used the
homology arms previously described by Keller et al. [11]. We
introduced the homology arms amplified by PCR using the RP11-
58B17 BAC clone as a template (BACPAC Resource Center
(BPRC), Children’s Hospital Oakland Research Institute, Califor-
nia, USA) into the pUC57 empty backbone, named pK0.
pKAS (from Knock-down/in Acceptor Site) was cloned using a
building block synthesized (GenScript, GenScript USA Inc.
Piscataway, NJ, USA) named pK1 containing the lox2272 site,
strong stop sequence and, loxP site and the hygromycin B
phosphotransferase (hph) gene. The PGK promoter obtained from
the pLVX.CMV.AcGFP.PGK.Puro vector (Clontech, Saint-
Germain-en-Laye, France) was cloned in the NotI and PstI sites
in pK1. In the following step, we introduced the neo cassette from
pcDNA 3.1 (Invitrogen) flanked by XmnI–SalI sites. Finally, we
cloned the whole cassette into pK0 (containing the the hROSA26
homology arms) using the AscI–MluI restriction sites.
The plasmid used to produce the RMCE event (pTRINA, from
Transfer Into Acceptor) was synthesized by GenScript. We
amplified this recombineering cassette using specific primers and
the product was cloned in the reverse orientation of the
pRRLsin18, a third generation lentiviral shuttle plasmid [23,24]
to generate pLV.TRINA.
pMDLg/pD64VRRE plasmid was generated by PCR muta-
genesis of the nucleotides encoding the aspartic acid substituted by
valine (D64V) using pMDLg/pRRE plasmid as template.
pRRLLsin18.CMVCre was cloned by ligation of the cre cDNA
obtained from LV-Cre-SD (12105, Addgene, Cambridge, MA,
USA) in the XbaI-SalI sites of donor pRRLsin18CMV lentiviral
shuttle vector.
All constructs were verified by sequencing with an ABIPrism
3000 sequencer (Applied Biosystems, Invitrogen).
DNA transfection
Cells were transfected with endotoxin-free DNA (Qiagen, Las
Matas, Madrid, Spain) and transfections were carried out in 6-well
plates unless otherwise stated. HEK293T and HEK293A cells
were transfected by the calcium-phosphate method using 5 mgo f
pKAS targeting plasmid and an eGFP control plasmid (pEGFP-
N1, Clontech) linearized using MluI and ScaI restriction enzymes
(New England Biolabs, IZASA, S.A. Barcelona, Spain), respec-
tively. After transfection cells were plated in their appropriate
medium in 6-cm tissue culture dishes (Nunc, LabClinics S.A.
Barcelona, Spain). Forty-eight hours later, G418 (Invitrogen) was
added to the culture medium in a final concentration of 500 mg/
mL. Medium was changed every 2–3 days, until isolated clones
were visible (10–14 days).
Quantification of transgene copy numbers by qPCR
analysis
The genomic DNA was extracted following standard procedure
and serial dilutions quantitated using NanoDrop ND 1000
Spectrophotometer (NanoDrop Technologies, Bonsai Tecnologies
Group SL, Alcobendas, Madrid, Spain). Real-time PCR was
performed using the SYBR Green methodology. The number of
integrated copies of pKAS plasmid in the 293AKAS cells was
measured as described in Butler et al. [25] with modifications.
PCR efficiency was examined with five dilutions of genomic DNA
and the specificity of individual gene primers was validated by the
melting curve at the end of each PCR assay. Standard curves were
obtained with diluted amounts of the pKAS plasmid from 0.01 pg
to 100 ng, corresponding 10
2–10
9 copies. Ct values obtained upon
amplification of neomicin, PGK and hygromycin regions con-
tained in pKAS using the specific primers listed below were
interpolated and the relative number of copies calculated. Cell
equivalents were calculated using Ct values of the single copy gene
Gusb on diluted samples of the genomic DNA. The qPCR
reaction was carried out under the following conditions: template
denaturation at 95uC for 10 min, followed by 40 cycles of
denaturation at 95uC for 15 s, annealing at 60uC for 20 s, and
extension at 72uC for 30 s. The primers used were:
qPGK Fw: CTTTGCTCCTTCGCTTTCTG
qPGK Rv: CGGAGATGAGGAAGAGGAGA
Product: 171 bp
qNEO Fw: TGAATGAACTGCAGGACGAG
qNEO Rv: ATACTTTCTCGGCAGGAGCA
Product: 171 bp
qHYGRO Fw: CTCGATGAGCTGATGCTTTG
qHYGRO Rv: GATGTTGGCGACCTCGTATT
Product: 165 bp
Gusb Forward: GTAGGGACAAGAACCACCCC
Gusb Reverse: TTGCTCACAAAGGTCACAGG.
Product: 148 bp
Standard PCR was performed using the following conditions:
template denaturation at 95uC for 1 min, followed by 30 cycles of
denaturation at 94uC for 30 s, annealing at 61uC for 30 s, and
extension at 72uC for 1.5 min, and a final extension of 5 min.
The primers used were: for pKAS integration detection
Fw primer #1 (Neo) GAAATGACCGACCAAGC
Rv primer #2 (R26LA) GCCCCTCAAATCTTACAGC
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and for RMCE product detection
Fw primer #3 (R26SA) GCCGAGACTTCTGGATG
Rv primer #4 (Cherry) GAACTCCTTGATGATGGCC
Product: 1250 bp.
Lentiviral vector production and transduction
Third-generation self-inactivating VSV-G-pseudotyped lentivi-
ral vectors were produced by transient transfection into HEK293T
cells as previously described [26]. Briefly, cells were seeded at
1.1610
7 cells/dish in 15-cm dishes the day before transfection.
Cells were transfected by the calcium phosphate method with 3 mg
pRSV-Rev, 3.75 mg pMD.2G (VSV-G), 13 mg pMDLg/pRRE (or
13 mg pMDLg/pD64VRRE for production of non integrative
lentiviral vectors) and 35 mg of transfer plasmid (pTRINA,
pRRL18sin.CMV-Cre or pRRLsin18.CMV-eGFP, unpublished
results). The medium was collected after 48 h, cleared by low-
speed centrifugation, and filtered through 0.45-mm-pore-size
PVDF filters. Viral stocks were concentrated by ultracentrifuga-
tion in SW28 Beckman rotor at 90,000 g (26,000 rpm) for 2 h at 4
uC. Pellets containing lentivirus were air dried and resuspended
O/N at 4uC in 400–600 ml of media. Viral titres were calculated
by FACS analysis on transduced HEK293T cells when vectors
expressed fluorescent proteins (transduction units/ml) and parti-
cles quantitated by qPCR on supernatants (particles/ml). Values
were around 10‘8t o1 0 ‘9 TU/ml and in a 1:100 TU/particles
ratio. Cells were transduced at different multiplicity of infection
(MOI) in media containing polybrene (8 mg/ml, final concentra-
tion). After 6 hours inocula was replaced with fresh medium, and
72 hours later the cells were analyzed by FACS or by starting
hygro selection (50 mg/mL to select HEK293A).
Western blot
Proteins were extracted following standard procedures in the
presence of Complete Protease Inhibitor Cocktail Tablets (Roche
Applied Science). Western blots were carried out by standard
methods on proteins transferred to PVDF using TransFi
(Invitrogen). Membranes were probed for cre with monoclonal
anti-Cre antibody (Novagen, EMD, Merck – Espan ˜a, Madrid
Spain) (1/2000) or anti-alpha tubulin (AbCam, Cambridge, UK)
(1/5000) in PBS/0.1% Tween-20 (PBSTween). Secondary
antibodies were HRP-conjugated goat antimouse IgG (Santa
Cruz Biotechnology, Inc., Heidelberg, Germany), and blots were
developed with ECL (GE Healthcare, Alcobendas, Spain).
Cytometry analyses
Flow cytometry analysis was performed after 72 hours post-
transduction. Cells were trypsinized and collected, washed twice in
culture-grade 1X PBS and analyzed in a FACS DIVA (Becton
Dickinson, San Agustı ´n del Guadalix, Madrid, Spain) sorter with
an appropriate laser for CherryFP excitation. In every case, 10,000
events were counted in triplicate.
Results
Design and strategy
The system was designed to promote RMCE on pre-tagged cells
with a genetic docking site containing heterospecific (incompatible)
RT sites (loxP and lox2272) [27,28] flanking a promoter-trapped
reporter gene cassette and targeted by the second cassette
delivered by IDLV concomitantly expressing cre recombinase in
a self-limiting manner (Fig. 1). Heterospecific RT sites are less
susceptible to intra-molecular excision/inversion. Lox2272 con-
tains two mutations in the 8 bp core compare to wt loxP site and
intra-molecular reaction is lower than 0,5% compared to
directional inter-molecular exchange ([29]).
To test our approach, we constructed a targeting vector (Fig. 1)
containing a selectable cassette (pKAS, from Knock-down/in
Acceptor Site) flanked by two homologous arms of the human
ROSA26 locus [11]. The cassette contains the weak but
Figure 1. Cre recombinase-mediated insertion and cassette exchange strategy. Structure of the genetic landing pad (KAS) and the
incoming construct (LV.TRINA) showing the more relevant elements: promoters PGK, EF-1a and SV40 in the neo cassette (black arrows), reporter
genes (coloured boxes), recombinase cre (green box), translation starting point (bended arrows), and polyA signals (crossed boxes). Triangles
represent the loxP (black) and lox2272 (white) sites. ROSA26 homology arms are pink-colored and lentiviral LTRs drawn as clear boxes flanking the
KAS and TRINA cassette respectively. For simplicity the CHYSEL and multicloning site downstream of the neo cassette are not indicated. The expected
resulting endpoints after RMCE reaction are depicted below. Symbols are kept for simplicity. ChFP, cherry fluorescent protein; LTR, long terminal
repeat.
doi:10.1371/journal.pone.0019794.g001
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stop signal and flanked by loxP and lox2272 an expression cassette
of the gene neo, which encodes neomycin resistance controlled by
the early promoter and polyA signal from SV40. This cassette is
followed by a promoterless reporter–selection cassette containing
the hph (hygromycin B phosphotransferase) gene, which encodes
hygromycin resistance. Cells bearing this genetic landing pad are
neo
R selected and undergo RMCE. The lentivirus shuttle plasmid
backbone (pTRINA, from Transfer Into Acceptor) contains the
promoterless gene of interest (GOI)–reporter cassette flanked by
the same heterospecific lox sites. The latter consists of a fluorescent
marker (cherry fluorescent protein [ChFP]) fused to the Picorna-
viridae porcine teschovirus CHYSEL sequence 2A [31] and a
multicloning site to clone every GOI. Finally the EF1alpha
promoter drives the expression of cre coding cassette placed
downstream of the loxP site. The complete construct was cloned in
an inverted position relative to viral LTR in order to preclude
premature transcriptional termination by polyA signals present in
the cassette that might prevent generation of genomic mRNAs
during production of lentiviruses.
Selected cells containing the genetic docking site are transduced
by VSV-pseudotyped IDLV particles and, upon reverse transcrip-
tion, nuclear lentiviral DNA structures of genome unit length [25]
are transcriptionally active to express cre recombinase from the
constitutive EF1alpha promoter. RMCE is initiated by exchanging
the cassette contained in the recombinant lentiviral genome
flanked by heterospecific loxP sites with that present in the genetic
docking site. The promoter trap design allows for easy isolation
and characterization of the targeted cells by double marker rescue
(antibiotic resistance and fluorescent protein). RMCE can be
performed with heterospecific target sites that are equally or
inversely oriented; we have selected the latter version, anticipating
that unwanted intersite-interactions would lead, in this case, to
inversion and not to excision preventing the expression of hph gene
from the PGK promoter.
Episomal recombination using an engineered genetic
landing pad
We tested the feasibility of our strategy in human HEK293 cells
by first addressing the ability of the cre expression plasmid,
pTRINA, to catalyze RMCE between two episomal substrates.
We used an assay based on transient co-transfection of supercoiled
pKAS and a pTRINA and measured both the frequency of
hygromycin-resistant (hygro
R) cell colonies and the percentage of
cells expressing of ChFP. Neither hygro
R colonies (Fig. 2A) or
ChFP+ cells (Fig. 2B at zero value on the horizontal axis, Fig. 2C)
appeared when cells were transfected with either pKAS or
pTRINA alone. On the contrary, hygro
R colonies (between 75–
300 colonies/assay; Fig. 2A) and cherry-expressing cells (ChFP+)
(between 10–20%; Fig. 2B, 2C) were obtained only when both
plasmids were transfected together. Considering transfection
efficiency close to 95% (data not shown), the frequency of hygro
R
or ChFP+ generated when only one plasmid was transfected is
lower than 3610
26. Remarkably the frequencies of RMCE
between two episomal substrates ranging from 3.5610
24 (ChFP+)
to 1.5610
25 (hygro
R), values that are indicative of a suitable
cassette exchange in our system and that are similar to data for
RMCE in selected tagged cells [13]. Discrepancies in the
frequencies obtained for hygro
R or ChFP+ could stem from
relative expression levels of the two reporter genes to select a
positive cell, as levels required for hygromycin resistance are not
comparable with the greatly enhanced sensitivity required to
detect a fluorescent single cell by FACS analysis ([32]).
We also used flow cytometry to quantify the number of cells
expressing ChFP+ cells 72 hours post-transfection under variable
relative amounts of pKAS together with fixed amounts of
pTRINA. Fig. 2C shows that with a 15-fold molar increase in
the relative amount of pKAS carrying the genetic landing pad
(1:20 compared to 1:1.3 ratio), the total number of ChFP+ cells
increases nearly 2-fold, suggesting that the availability of the
docking site is a limiting element for RMCE under conditions of
sufficient levels of transient cre expression. When the reversible
assay was carried out, we found that up to10-fold lower molar
ratio of pTRINA related to pKAS is efficient enough to promote
RMCE (data not shown).
Together the data obtained using either hygro (Fig. 2A) or
ChFP (Fig. 2B, 2C) markers, demonstrate that plasmids bearing
the genetic docking and the cre expressing cassettes are both
required to generate promoter trapping. Remarkably, the number
of RMCE events can vary with the relative amount of the cre-
expressing plasmid (Fig. 2A).
We hypothesized two different scenarios for the generation of
ChFP+ and hygro
R colonies: (i) random integration of pTRINA
and of pKAS accompanied by independent promoter trap events;
and (ii) legitimate cassette exchange, when recombination occurs
simultaneously between two pairs of heterospecific RT by the
action of cre. Given that the spontaneous frequency of appearance
of ChFP+ and hygro
R cells is lower than 3610
26, the use of a
double checkpoint renders scenario 1 unlikely, as the frequency of
appearance of double-positive cells by two independent random
promoter trap events will be close to one cell in one billion of the
transfected cells. The enrichment strategy allows direct selection of
SSR, as random integration is likely to be transcriptionally silent
and will not resist hygromycin selection or become red fluorescent.
Integrase-deficient lentiviruses can promote RMCE in
randomly integrated copies of genetic docking target
We showed that pTRINA catalyses site-specific cassette
exchange between two episomal plasmids flanked by heterospecific
lox sites. We next investigated whether RMCE can also be
achieved between a chromosomal DNA substrate and circular
intermediate lentiviral genomes formed during reverse transcrip-
tion in the absence of a functional integrase. As a first approach,
we targeted randomly integrated genetic landing pad copies on
pooled (n.80) neo
R HEK293A cells (293AKAS) obtained by
transfection with pKAS and G418 selection. Transduction at low
MOI (2 transduction units/cell) of the lentivirus IDLV-TRINA
into the pooled 293AKAS was applied to measure the frequency of
RMCE by the lentivirus. Upon cre recombinase-catalyzed SSR,
the promoterless hygromycin and ChFP genes are placed under
the transcriptional control of PGK and EF1alpha promoters,
respectively. Both hygro
R and red colonies (ChFP-expressing cells)
were counted as an approximate quantification of the RMCE
process. As shown in Fig. 3A, only when cre recombinase is
expressed from the IDLV virus (IDLV-TRINA), 293AKAS cells
were able to become ChFP+ or hygro
R cells. Remarkably, all
hygro
R phenotypes also displayed the ChFP+ phenotype, as
observed by fluorescence microscopy analysis, thus demonstrating
that legitimate RMCE was occurring (data not shown). A rough
estimation of the frequencies at this MOI is, on average, 400
hygro
R colonies in 1610
6 neo
R cells, close to an RMCE frequency
of 4610
24, or close to1610
22 in the case of ChFP+ measurement.
The directionality in the recombination reaction between loxP
and lox2272 sites explains the performance revealed by the
frequency of hygro
R cells as well as on the appearance of cherry-
expressing cells. Although cre-mediated recombination between
incompatible lox sites is almost negligible [33], the rescue of
Safe Viral Delivery to Genome Targeted Cells
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19794Figure 2. Plasmid-mediated RMCE by transient transfection. (A) Hygromycin-resistant colonies obtained upon transfection of HEK293A cells
with the indicated plasmids containing the genetic landing pad (pKAS) or the transfer plasmid (pTRINA) expressing cre-recombinase at two different
relative amounts (low and high [pTRINA]). Colonies were stained after ten days under conditions of selection. (B) Microphotographs under brightfields
(left) and fluorescent light (right) of the transfected cultures with the indicated plasmids. (C) Number of cells expressing cherry fluorescent protein
(ChFP+) upon RMCE on HEK293A cells measured by FACS analysis. Variable amounts of pKAS were used with a constant amount of pTRINA as is
indicated. Transfections were made in duplicate, and the results shown in both A and B are from one representative experiment out of three.
doi:10.1371/journal.pone.0019794.g002
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R cells could be due either to the excision reaction in cis in
the pKAS construct leading to the hph gene joined downstream to
the PGK promoter, or to leaky expression resulting form RNA
39readthrough [34]. To study these phenomena, we transduced
293AKAS cells at low MOI (2 TU/cell) with a lentivirus
expressing cre recombinase alone (pRRLsin18.CMVcre) and
counted the number of hygro
R colonies obtained. As shown in
Fig. 3 (right), not a single colony was obtained, thus representing a
frequency below 1610
26 illegitimate recombination events in our
system. Such values cannot be raised by increasing the MOI, given
that up to 50 TU/cell were used and did not yield hygro
R colonies
(data not shown). These data strongly support the idea that our
strategy enables the direct selection of RMCE, because random
integration is transcriptionally silent and cells do not survive G418
or hygromycin selection.
Viral transduction titrates the efficiency of RMCE
Having shown that the non-integrative lentivirus can consider-
ably increase the frequencies of RMCE, we performed assays to
assess whether the strategy could be improved merely by
modifying the lentivirus transduction procedure. As HEK293A
cells are easily transduced, we studied the effect of the MOI on the
frequency of SSR. Fig. 3 shows that by increasing the amounts of
IDLV.TRINA, the number of hygro
R colonies (B) and ChFP+
cells (C) parallels the MOI in the range of 0.1 to 10 TU/cell. The
relative effective targeting frequency (ETF), measured as the ratio
between number of hygro
R/ChFP+ cells and total number of
G418
R 293AKAS cells plated, is the most reliable measurement of
RMCE, given that it is difficult to detect the total number of cells
transduce as there is no an additional reporter gene. Then there is
no experimental data to calculate the absolute targeting frequency
Figure 3. Randomly chromosomal integrated copies of the genetic landing pad KAS are targeted by IDLV expressing the TRINA
cassette. HEK293A cells resistant to G418 (293AKAS) were pooled and transduced with low MOI (2 transduction unit/cell) of IDLV-TRINA. (A)
Transduced cells were selected with hygromycin and the colonies counted. The figure shows stained plates after selection of cells MOCK-transduced
(LV.eGFP, left) or transduced with IDLV-TRINA (center) or IDLV-Cre (right). (B) Quantification of RMCE frequency in 293AKAS cells by culturing under
selection conditions with hygromycin upon transduction at different MOI with IDLV-TRINA . (C) Quantification of RMCE frequency in 293AKAS cells by
FACS analysis of ChFP+ upon transduction at different MOI with IDLV-TRINA as in B. Triplicate cultures were transduced, FACS analyzed in triplicate.
Average +/2SD is represented. (D) Western blot to detect cre expression in pooled 293AKAS cells at different points after transduction with
IDLV.TRINA (MOI 2 TU/cell). The alpha-tubulin protein was used as a loading control (bottom panel). Results in A and C are from one representative
experiment out of three. ETF: Effective Targeting Frecquency: ratio between hygro
R (B) or ChFP+ (C) and the number of total G418
R cells plated for
transduction.
doi:10.1371/journal.pone.0019794.g003
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of transduced cells. ETF is between 2610
24 and 7610
25 hygro
R
and, importantly, between 1610
22 and 8610
23 ChFP+ at MOIs
of 10 TU/cell and 5 TU/cell. These values fell 10- to 20-fold
when low MOIs were used. The frequencies obtained at higher
MOI are 10-fold higher than published for lipofection and 300-
fold higher than for electroporation by antibiotic resistance [13].
However, if ChFP+ values are considered, then 1,000- to 10,000-
fold increases were obtained. The result suggests that the level of
cre, which is controlled by its own activity as the expression
cassette is flanked by heterospecific loxP sites (Fig.1) and diluted
with cell division, is the major bottleneck in the RMCE. We have
addressed the kinetics of expression of cre recombinase at different
time points upon transduction of 293AKAS cells with IDLV.-
TRINA at MOI of 2 TU/cell. As shown in Fig. 3D, levels of cre
increases from 12 to 72 hours post transduction and start
decreasing to almost undetectable levels at seven days post
transduction. Similar results were observed by immunfluorescence
on transduced cells, as at 5 days post transduction the protein is
almost undetectable (data not shown). Besides, the lack of cre
recombinase expression in untransduced cells supports the idea
that expression of cre encoded by IDLV.TRINA transduction is
necessary to obtain the ChFP+ and hygro
R phenotypes.
However, importantly, numbers of cells undergoing RMCE
could easily be raised with a concomitant increase in the MOI, a
situation resembling that of cells which are difficult to transduce,
whereas at MOIs low enough to ensure minimal—if any—effect
on cellular viability or integrity (2 TU/cell), efficiency is high
(1610
23).
We also studied the stability of the expression of both markers.
Cultures of hygro
R cells were maintained under selective
conditions for four weeks and periodically analyzed using FACS
to quantitate the absolute number of ChFP+ cells related to
hygro
R . Although numbers of ChFP+ cells were slightly different,
nearly 60% were positive after one month in culture (data not
shown). Even when cells undergo RMCE correctly, i.e. by
positioning each genetic element in the predicted manner (thus
allowing the selection of the targeted cells), expression for the
fluorescent marker was not stable under hygromycin selection, a
phenomenon described in other RMCE strategies [13].
IDLV-TRINA targets genomic landing pad by legitimate
RMCE
We verified the recombination reaction by PCR. Genomic
DNA was prepared from neo
R cultures of 293AKAS selected with
hygromycin for 10 and 20 days after transduction with
IDLV.TRINA (MOI 2 transduction units/cell). Control DNA
was obtained from untransduced HEK293A and 293AKAS
cultures transduced with an unrelated-IDLV expressing the eGFP
reporter gene (pRRLsin18.CMVeGFP). Conventional PCR was
conducted using specific primers to detect integrated KAS or the
RMCE product (Fig. 4) that generated bands of 1450 bp and
1250 bp, respectively. We also studied the random integration of
the IDLV.TRINA on the same samples by qPCR using LTR-
specific primers [25] and found less than one integration copy/cell
according to standardized curves (data not shown). The predicted
1250 bp product indicating cassette exchange between KAS and
TRINA only appeared when cells were transduced with
IDLV.TRINA (Fig. 4 lane 10 and 11). In contrast, no PCR
product was generated with DNA from control cells (HEK293A,
293AKAS and 293AKAS.IDLVeGFP; Fig. 4 lanes 7, 8 and 9).
Importantly, the absence of the 1.5 Kb band in IDLV.TRINA
transduced 293AKAS cultures (Fig. 4, lanes 4 and 5) strongly
supports the idea that the RMCE reaction in our conditions is
highly efficient. Then all the copies of pKAs randomly integrated
that were stimated in 1,8 copies per cell by qPCR, are submitted to
RMCE.
Discussion
The purpose of the experiments presented here was to provide
proof-of-principle that non-integrative lentiviruses can be used in
cell-mediated strategies for freely modifying the murine and
human genome by RMCE. We showed that legitimate site-specific
recombination governed by transcription from an integration-
deficient lentiviral vector (IDLV.TRINA) promotes exchange of
replicative viral intermediates flanked by heterospecific lox sites
with equally flanked chromosomal DNA substrate (KAS). The
system is simple, yet highly efficient, and promotes RMCE at
frequencies not previously reported, to our knowledge, in selected
cells harboring integrated docking sites, although we targeted
randomly integrated copies instead of using HR. The activation of
the reporters (ChFP and hph) relies on the autolimited expression
of the recombinase and is not based on the cellular repair
machinery or cre-like activity present.
Despite restrictions due to the specific features of the strategy,
we observed that 100% of the recovered clones were selected as a
result of RMCE by coupling promoter trap strategy with SSR as
published elsewhere [2,13,16,27,35]. However, it is noteworthy
that frequencies between 1610
23 and 1610
22 are 1,000-fold to
100,000-fold higher than previously reported using either lipofec-
tion or electroporation, respectively. Besides highlighting the
beneficial features raised from properties of lentiviral vectors, i.e.
easy cloning and production of the vector and high level of cell
viability upon transduction, we showed that the major advantages
of KAS/TRINA are based on the following: (i) self-limiting
expression of the cre recombinase delivered by the viral vector; (ii)
transient expression from the IDLV; and, finally (iii) scalability of
the frequency of RMCE simply by increasing the MOI for
transduction. Importantly, frequencies of RMCE are two log units
above the very low frequency of integration of the IDLV,
estimated between 1610
24 to 2610
25 integrants/viral genome
copies [36,37], which renders its selection during the procedure
negligible, given frequencies of RMCE close to 1% of the
transduced cells at low MOIs (Fig. 3C). We observed that our
results were proof-of-principle by using cells prone to transduction
and randomly integrated copies. The number of integrations of the
docking cassette in the pooled 293AKAS cells is around 1.8 copies
per cell, a data that allows to compare the frequencies obtained
using our strategy with those obtained with RMCE on tagged cells
at single specific loci [12,16,38], then targeting 2 copies per cell.
Indeed, given that pKAS is inserted in multiple loci, positional
effects due to random insertions underestimate our frequencies of
RMCE compared to gene replacement at hprt or ROSA26 loci that
are prone to recombination, and RMCE appears to address all
KAS-targets (PCR test in Fig. 4). Limited expression of cre
recombinase is controlled by its own enzyme activity, as it
expression cassette in pTRINA is flanked by lox sites and the non-
episomal nature of the IDLV intermediates switches the expression
off.
Our genetic approach, Kas/TRINA, could be used to modify
refractory cells [14] by increasing the amount of virus or
establishing efficient and selective transduction protocols. This
system is affordable, efficient, and easy, and can be applied in
large-scale assays or low-to-medium throughput assays. Therefore,
we consider that our strategy may be a useful tool for genetic
manipulation, not only of tagged cell lines, but also of ESCs and
iPSCs. Although similar to the strategies used in other reports [2],
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reproducible platform to study gene function in almost any cell
type. However, the novelty of delivering recombinase in the same
lentiviral vector in a non-integrative and self-limiting manner by
means of lox flanking eliminates enzyme toxicity [17] and the need
for additional and independent gene transfer [39].
The availability of cell lines tagged at predefined loci (ROSA26,
AAVS1, hprt) with heterospecific lox sites in combination with att or
frt sequences should facilitate—through repeated transduction with
IDLV encoding different recombinases—the study of multiple
genetic elements. The strategy can be further developed using
engineered transgenes containing specific recombinase sites and will
enable the generation of secondary cells lacking a particular factor
and leaving only a localized genetic scar. Our strategy can be
applied in the screening of early molecular events leading to stem
cell differentiation and disease, in genetic simulation of disease
models, and, importantly, in genetic studies using iPSC technology.
In addition, the genetic homogeneity of the cells makes chemical
and genetic screening approaches feasible, easy, comparable, and
reliable. The efficiency and lengthy process of generating knock-in
mousemodelsshouldbeshortened bycombiningestablishedEScell
lines bearing the docking KAS or KAS-like derivatives with
available lentiviral technology for microinjection to generate KI
or KD by RMCE.
We further demonstrate the powerful technology of viral vectors
based on non-integrative lentivirus, an achievement that will
contribute to the development of novel and safer strategies for
gene transfer.
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